Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News SAB Biotherapeutics Inc SABS

Alternate Symbol(s):  SABSW

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1... see more

Current News (NDAQ:SABS)

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire March 19, 2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire March 17, 2026

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire March 17, 2026

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

GlobeNewswire March 10, 2026

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

GlobeNewswire March 9, 2026

SAB BIO to Participate in Upcoming Investor Conferences

GlobeNewswire March 2, 2026

SAB BIO to Participate in Upcoming Investor Conferences

GlobeNewswire February 4, 2026

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

GlobeNewswire January 7, 2026

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026
View More News ››

Opinion & Analysis (NDAQ:SABS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SABS)

RE:SABS....trading at $3.40 now

Looked at my stock ticker yesterday morning. Stock at over $5 but dropping. Managed to sell for $4.32. Dropped that much in just the...
UnknownUnknowns - July 23, 2025

SABS....trading at $3.40 now

Did somebody say FOMO????
Iseneschal - July 21, 2025

RE:SABS....1st scalp of the a.m on the NR

SABS is buying me lunch today. Cheers !!!! No FOMO for this Cowboy
Iseneschal - July 21, 2025

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
coolfooldumbguy - July 21, 2025

SABS....1st scalp of the a.m on the NR

Lunch money works for me ; )
Iseneschal - July 21, 2025

Sheesh!

Where is everybody?  People should be discussing this one.  Technicals are lining up nicely.  Just waiting for my trigger...
dragshot - June 1, 2023
View more Bullboard ››

TAG Oil Ltd.

TAG Oil Ltd.

TAG Oil Ltd., together with its subsidiaries, engages in the exploration, development, and production of oil and gas in ...
View More »

Podcasts